Theyre both central nervous system (CNS) stimulant drugs that work by increasing levels of certain neurotransmitters in the brainbut thats where the similarities end
Furthermore, urinary infections are not significantly higher for PTDM patients and can be managed with standard treatments. Combination therapies involving GLP-1 agonists and SGLT-2 inhibitors have shown promise in managing co-morbidities associated with liver transplant recipients
What the New Tirzepatide Hormone Therapy Study Found Researchers published a retrospective cohort study in The Lancet Obstetrics, Gynaecology, & Womens Health in March 2026
As depicted in Figure 1, dipeptidylpeptidase-4 (DPP-4) is an ubiquitously expressed transmembrane protein that removes N-terminal dipeptides from various substrate hormones, chemokines, neuropeptides and growth factors
However, these mechanisms are complex, and more research is needed before GLP-3 treatments become standard care